View larger
Human SARS-CoV-2 Nucleocapsid Protein (N) IgA, IgG, and IgM Multiplex FIA/FLISA kit
FIA-COVID19-N-M
Data sheet
| Background | Upon viral infection or vaccination, the humoral immune system responds first by producing the immunoglobulin IgM, followed later by IgG which can convey long lasting immunity. IgA, a mucosal immune response, is also found in blood. By testing for IgM, IgG, and IgA in human serum and plasma, researchers may identify those who have been exposed to the SARS-CoV-2 virus and mounted some level of immune response. Researchers may further understand the immune response over the course of infection and recovery, antibody generation from this multiplex FIA kit for SARS-CoV-2 Nucleocapsid Protein (N) IgA, IgG and IgM. |
| Assay principle | The Human IgA, IgG, and IgM Multiplex FIA/FLISA Kit employs an indirect fluorescent probe technique that measures IgA, IgG, and IgM in human plasma, serum, and cell culture samples in less than 2.5 hours. Purified SARS-CoV-2 Nucleocapsid Protein (N) antigen is coated on the surface of microwells. Diluted patient serum is added to wells, and the SARS-CoV-2 Nucleocapsid Protein (N)-specific IgA or IgG or IgM, if present, binds to the antigen. All unbound materials are washed away. After adding fluorescent secondary antibody, it binds to the IgA-or IgG or IgM-antigen complex. The fluorescent signal generated is proportional to the amount of SARS-CoV-2 Nucleocapsid Protein (N) specific IgA or IgG or IgM antibody in the sample. The results are read by a fluorescent plate reader compared in a parallel manner with calibrator and controls. |